Cardiomyocytes Market size is expected to reach USD 12 Billion by the end of 2036, growing at a CAGR of 10% during the forecast period, i.e., 2024 -2036. In the year 2023, the industry size of cardiomyocytes was USD 5 Billion. The market is thriving on the back of the rising incidence of cardiovascular diseases in the world. According to research an estimated 7% of men and around 4.5% of women suffer from heart-related diseases. The heart's rhythmic beating is regulated by cardiomyocytes, which are the cells that produce contractile force in an intact heart. Hence, increasing the demand for cardiomyocyte therapies in the world.
In addition to these, factors that are believed to fuel the market growth of the cardiomyocytes market include the growing geriatric population. Research shows that an estimated 771 million individuals worldwide were 65 years of age or older in 2022, making up about 10% of the world's population. This increases the demand for cardiomyocyte therapies as older people are more susceptible to cardiovascular diseases.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~10% |
|
Base Year Market Size (2023) |
~ USD 5 Billion |
|
Forecast Year Market Size (2036) |
~ USD 12 Billion |
|
Regional Scope |
|
Type (Human iPSC-Derived Cardiomyocytes, Rat Cardiomyocytes)
The human iPSC-derived cardiomyocytes segment is predicted to account for 60% share of the cardiomyocytes market by 2036. The segment growth can be attributed to the rising prevalence of cardiovascular diseases, such as coronary heart disease, stroke, hypertension, and congestive heart failure. According to the data published by the World Health Organization cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Cardiomyocytes produced from induced pluripotent stem cells (iPSC) can improve the precision, efficacy, and accuracy of identifying cardiovascular damage hazards in drugs as well as non-pharmaceutical methods. Hence, increasing the demand for human iPSC-derived cardiomyocytes in the cardiomyocytes market.
Application (Independent assays, Cardiac Disease Modeling, Cardiac safety & Toxicity)
Cardiac safety and toxicity segmented in cardiomyocytes market is estimated to gain a significant share during the forecast period. The segment growth can be attributed to the global rise in cardiotoxicity brought on by an increased prevalence of cancer. Cardiotoxicity is the term for heart damage caused by several cancer medications or treatments and results in cardiac diseases including but not limited to arrhythmia, myocardial infarction, and myocardial hypertrophy. Research by the World Cancer Research Fund Internation shows that there were an estimated 18.1 million cancer cases around the world in 2020. Thus showing significant growth in the cardiomyocyte market in the forecast period.
Our in-depth analysis of the Cardiomyocytes market includes the following segments:
|
Type |
|
|
Application |
|
|
End-Users |
|
North America Market Forecast
The cardiomyocytes market in the North American region, amongst the market in all the other regions, is anticipated to hold the largest with a share of about ~35% by the end of 2036. The market growth in the region is expected to grow on account of the presence of major key players such as Axol Bioscience Ltd, Cell Applications Inc., Cellular Dynamics International, and R&D Systems Inc. in the region. Moreover, the Boston-Cambridge biotech cluster and San Francisco Bay Area Silicon Valley in the United States serve as the epicenter of cardiomyocyte research investments and entrepreneurship. Additionally, the high prevalence of cardiovascular disease due to unhealthy lifestyles in the region is also expected to further propel the market growth. According to data published by a government website about 695,000 people in the United States died from heart disease in 2021. Increasing the demand for newer and more effective forms of treatment like cardiomyocyte therapies in the region.
APAC Market Analysis
The Asia Pacific market is estimated to be the second largest, registering a share of about ~20% by the end of 2036. The market’s expansion can be attributed majorly to the increasing demand for cardiac testing in fast-emerging countries such as India, China, Vietnam, and Indonesia, as a result of rising cardiovascular diseases in the region. According to research around 5 million people in India died due to cardiovascular diseases in 2020 and an estimated 4.58 million deaths occurred in 2020 in China due to cardiovascular disease. Furthermore, the growing aging population of this region due to increasing longevity and falling fertility is also expected to propel the market growth. For instance, in 2020 there were an estimated 140 million people aged 60 and above in India, and in 2019 an estimated 250 million people in China were aged 60 years or older. Thus, increasing the demand for cardiomyocytes in the Asia-Pacific region.
Abbott Park, Illinois /PRNewswire/ -- The world leader in science-based nutrition, Abbott (NYSE: ABT), has announced the introduction of its new PROTALITYTM brand. The first product in this range to cater to the increasing number of adults who want to lose weight without sacrificing healthy nutrition and muscle mass is the high-protein nutrition smoothie.
Novartis announced that Fabhalta® (iptacopan) has been approved by the U.S. Food and Drug Administration (FDA) as the first oral monotherapy for the management of adults suffering from paroxysmal nocturnal hemoglobinuria (PNH)1. A Factor B inhibitor, fabhalta functions proximally in the immune system's alternative complement pathway, offering complete regulation of the destruction of red blood cells (RBCs) both inside and outside of blood vessels (intra- and extravascular hemolysis [IVH and EVH]).
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?